



Minutes of the annual general meeting of shareholders (the "Meeting") of Kiadis Pharma N.V. ("Kiadis" or the "Company") held on Thursday 25 June 2020 at 10:00 CEST.

In view of the COVID-19 pandemic and pursuant to the COVID-19 Justice and Security (Interim Measures) Act (*Tijdelijke wet COVID-19 Justitie en Veiligheid*) (the "COVID-19 Act"), the Meeting was held on a fully virtual basis. Reference is made to the notice, agenda and explanatory notes to the agenda in relation to the Meeting that Kiadis made available on 13 May 2020.

Agenda item 1 – Opening and announcements

The Articles of Association stipulate that the Chairman of the Supervisory Board acts as chairman at general meetings. Consequently, Mr. Wegter chairs the Meeting as its Chairman.

The Chairman opens the meeting at 10:03 CEST and welcomes the shareholders that are dialled in and participating on a virtual basis in the Meeting.

The Chairman expresses the hope that everybody is in good health in this special period. At Kiadis the primary goal is to protect the health and safety of Kiadis' employees, partners and shareholders. This is the reason why Kiadis has decided to use the opportunity created by the special Dutch temporary COVID-19 Act to hold a completely virtual annual general meeting of shareholders. By using this virtual set-up of the 2020 annual shareholders meeting there is no health risk for shareholders and Kiadis meeting participants.

The Chairman introduces the participants from the Kiadis side who are participating in the Meeting:

- Mr. Arthur Lahr, Kiadis' CEO and sole member of the Management Board;
- Mr. Paul van Hagen, Kiadis' Senior Vice President of Finance;
- Ms. Margot Hoppe, Kiadis' General Counsel;
- Ms. Lindsay Albert, Mr. Herman van Meel and his successor, Mr. Frederik Croiset van Uchelen, from KPMG Accountants, Kiadis' external auditor;
- Mr. René Rieter, civil law notary from the law firm Bird & Bird; and
- Mr. Michiel Wurfain, lawyer from the law firm Bird & Bird.

The Chairman makes the following announcements:

- Shareholders that are registered in Kiadis' shareholders register have been sent written notice 42 days before the day of the Meeting.

DRAFT

- In addition, shareholders have been notified by means of a public announcement made on Kiadis' website (www.kiadis.com) 42 days before the day of the Meeting.
- In accordance with the provisions of the COVID-19 Act and the agenda with convocation notice for the Meeting, shareholder voting rights have been exercised prior to the Meeting by authorizing the proxy designated by Kiadis in accordance with the instructions included in the Meeting convocation documents. Voting was possible until Thursday 18 June 2020 15:00 CEST.
- The documents for the Meeting have been available for inspection as of the day of notice of the Meeting. These documents have been available on the Kiadis website by way of download from www.kiadis.com as of the day of notice of the Meeting.
- Mr. René Rieter, civil law notary (*notaris*) from the law firm Bird & Bird will prepare the minutes of the Meeting.
- Holders of 15,080,891 ordinary shares are attending or represented at the Meeting on a virtual basis. Consequently, together a nominal share capital of €1,508,089.10 is represented, constituting a total of 37.66 % of Kiadis' issued share capital. A total of 15,080,891 votes can be cast.
- Because of the virtual format of the Meeting and the fact that voting has been done before the Meeting, the meeting order shall be as follows:
 - First, all agenda items will be dealt with by the Kiadis representatives and - as for item 4 - the external auditor
 - Thereafter and in line with the stipulations in the convocation documents and the Protocol for Asking Questions Before and During the Meeting, at the beginning of agenda item 16 (Any other business), all questions that have been submitted before the Meeting as well as all of the follow-up questions that have been asked during the Meeting will be answered.
 - After answering the questions, the voting results shall be released.
 - The Chairman will close the Meeting after the voting results are shared with the Meeting participants.
- All shares have been voted on, on the basis of powers of attorney and voting instructions that have been received by Kiadis before the Meeting. These powers of attorney have all been granted to the Chairman.
- Blank votes, invalid votes and abstentions have been considered as not having been cast but are counted towards a quorum.
- The questions asked before the Meeting and the answers thereto are made available by way of download on Kiadis' website (www.kiadis.com) after the Meeting.

The Chairman moves to the next agenda item.

Agenda item 2 – Annual Report for 2019 by the Management Board

At the request of the Chairman, Kiadis' CEO Mr. Arthur Lahr comments on the report of the Management Board included in the Annual Report for 2019. Subsequently and at the request of the

DRAFT

Chairman, Mr. Paul van Hagen, Senior Vice President of Finance, comments on the financials set out in the Annual Report for 2019.

Mr. Lahr and Mr. Hagen inform the Meeting on the basis of a presentation that is cast during the Meeting and is made available by way of download on Kiadis' website (www.kiadis.com) following the Meeting.

The Chairman moves to the next agenda item.

Agenda item 3 – Advisory vote on the Remuneration Report for 2019

The full text of the Remuneration Report for 2019 is attached as an appendix to the agenda for the Meeting and is included in the Annual Report for 2019 on pages 43 to 48. On 1 December 2019, Dutch legislation implementing the revised EU Shareholders' Rights Directive came into force. Under this new legislation, the Remuneration Report must be submitted for an advisory vote by the general meeting of shareholders.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 4 – Financial Statements for 2019

It is proposed to adopt the Financial Statements for 2019. The Financial Statements, as drawn up by the Management Board, were approved by the Supervisory Board on 30 April 2020 and published on 30 April 2020. The Financial Statements can be found in the Annual Report for 2019. The Financial Statements have been audited by KPMG Accountants, Kiadis' external auditor, and the auditor's report can be found as of page 102 up to and including page 111 of the Annual Report for 2019.

At the request of the Chairman, Mr. Herman van Meel from KPMG Accountants gives an explanation of the audit of the Annual Report for 2019.

Mr. Van Meel gives a brief explanation on:

- the audit approach, including the materiality threshold applied;
- the three key audit matters:
 - classification of expenses in the statement of comprehensive income;
 - accounting for a significant business combination, i.e. the CytoSen acquisition; and
 - the discontinuation of ATIR and related restructuring; and
- the going concern statement, noting that, although KPMG's opinion is not modified in relation to this matter, the audit opinion includes an emphasis of matter paragraph which indicated that at the time of the opinion Kiadis had insufficient cash and cash equivalents to meet its working capital requirements through the subsequent twelve months and therefore depends on an equity financing, a non-dilutive financing or strategic transactions along with the uncertainties on capital markets caused by COVID-19 for realizing aforementioned transactions, which conditions indicate the existence of a material uncertainty which may cast significant doubt about its ability to continue as a going concern.

DRAFT

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 5 – Release from liability of the members of the Management Board

It is proposed that the members of the Management Board will be released from liability in respect of their managerial activities in 2019.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 6 – Release from liability of the members of the Supervisory Board

It is proposed that the members of the Supervisory Board will be released from liability in respect of their supervisory role in 2019.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 7 – Adoption of revised Remuneration Policy for the Management Board and the Supervisory Board

In accordance with Dutch law implementing the revised EU Shareholders' Rights Directive, the Supervisory Board proposes to the Meeting to adopt the Remuneration Policy for the Management Board and the Supervisory Board. The full text of the new Remuneration Policy is attached as an appendix to the agenda for the Meeting. The resolution to adopt the Remuneration Policy requires a majority of at least 75% of the votes cast. Once adopted, the Policy will become effective with retrospective effect from 1 January 2020 and will replace the Remuneration Policy for the Management Board and remuneration for the Supervisory Board that were approved by the general meeting of shareholders on 29 March 2019. The Remuneration Policy is made available by way of download on Kiadis' website (www.kiadis.com) following the Meeting.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 8 – Remuneration of members of the Supervisory Board, including the granting of options

In the general meeting of shareholders held on 29 March 2019, a cash remuneration for members of the Supervisory Board was adopted and became effective from 29 March 2019 and to be applied as of the financial year 2019.

It is proposed to the Meeting to confirm that the cash remuneration for the Supervisory Board as resolved upon on 29 March 2019 under the newly adopted Remuneration Policy as proposed in agenda item 7 shall remain the same for the coming years for as long as the newly adopted Remuneration Policy remains in force.

DRAFT

Assisted by an independent compensation consultancy firm, the Nomination and Remuneration Committee has further reviewed and analyzed whether the remuneration of the members of the Supervisory Board is competitive with its peer group. Based on a benchmark of the relevant peer group, the Nomination and Remuneration Committee has concluded that to be competitive from a compensation perspective with peers and to align its remuneration offering with market compensation levels specifically in relation to the members of the Supervisory Board, the members of the Supervisory Board should also be granted options in 2020 under Kiadis' share option and stock appreciation rights plan.

Although not in line with best practice provision 3.3.2 of the Dutch Corporate Governance Code – which states that Supervisory Board members may not be awarded remuneration in the form of shares or rights to shares – the Management Board and the Supervisory Board regard the proposed granting of options to represent a critical remuneration component to attract and retain needed industry experience and competence.

With due observance of the new Remuneration Policy (agenda item 7), it is further proposed that for the year 2020 and in addition to the cash remuneration determined in the 29 March 2019 general meeting of shareholders, the remuneration of the members of the Supervisory Board shall also include options to be granted in 2020 under Kiadis' share option and stock appreciation rights plan.

It is proposed that each member of the Supervisory Board is entitled to a grant of 145,000 share options. The number of options is based on the median of the peer group and the Hull and White option valuation model, a widely accepted methodology, and valued as per 1 January 2020. These options will be granted automatically under the terms of Kiadis' share option and stock appreciation rights plan on the date of the approval and adoption of this agenda item 8 by the Meeting and will not require any further approval by the Supervisory Board or Kiadis.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 9 – Reappointment of Mr. Robert Soiffer as member of the Supervisory Board

The Supervisory Board proposes to reappoint Dr. Robert Soiffer as a member of the Supervisory Board because of his relevant knowledge and extensive experience and qualities as Supervisory Board member as demonstrated during his past period as member of the Supervisory Board. Dr. Soiffer's CV was included in the explanatory notes to the agenda for the Meeting. Robert Soiffer will remain an independent member of the Supervisory Board within the meaning of the Dutch Corporate Governance Code. He will be reappointed for a period of four years with effect from the date of the Meeting, ending by close of the annual general meeting of shareholders to be held in 2024.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 10 – Reappointment of Mr. Berndt Modig as member of the Supervisory Board

The Supervisory Board proposes to reappoint Mr. Berndt Modig as a member of the Supervisory Board because of his relevant knowledge and extensive experience and qualities as Supervisory Board member as demonstrated during his past period as member of the Supervisory Board. Mr.

DRAFT

Modig's CV was included in the explanatory notes to the agenda for the Meeting. Berndt Modig will remain an independent member and the financial expert of the Supervisory Board within the meaning of the Dutch Corporate Governance Code. He will be reappointed for a period of four years with effect from the date of the Meeting, ending by close of the annual general meeting of shareholders to be held in 2024.

Mr. Berndt Modig shares his motivation for remaining on the Supervisory Board by means pre-recorded audio-message.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 11 – Appointment of KPMG Accountants N.V. as Kiadis Pharma's external auditor for the financial year 2020

It is proposed to appoint KPMG Accountants N.V. as Kiadis' external auditor for the financial year 2020.

Due to auditors independence requirements, Mr Frederik Croiset van Uchelen will succeed Mr. Herman van Meel as responsible KPMG audit partner from book year 2020.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 12 – Delegation to the Management Board of the authority to issue shares and grant rights to acquire shares

In order to be able to raise capital through the issuance of shares, service the option rights of Kiadis managers and employees and to have financial flexibility, it is desirable for the Management Board to have appropriate authority to issue shares and to grant rights to subscribe for shares. It is therefore proposed that the authority to issue shares and to grant rights to subscribe for shares in the capital of Kiadis is delegated to the Management Board up to Kiadis' authorized share capital included in its Articles of Association from time to time, and that such authorization shall be granted for a period of five years following the date of the Meeting, and consequently until (and including) 25 June 2025.

In the general meeting of shareholders held on 29 March 2019, the shareholders already approved a conditional amendment of the Articles of Association, introducing preference shares in Kiadis' authorized share capital. As per agenda item 15 of the Meeting, the Management Board and the Supervisory Board have decided to now implement this previously approved introduction of preference shares in Kiadis' authorized share capital. It is noted that if the amendment of the Articles of Association as proposed in agenda item 15 is adopted and implemented, the proposed delegated authority to issue shares and grant rights to subscribe for shares will effectively regard and encompass both Kiadis' ordinary shares as well as its preference shares, which will empower the Management Board, with the approval of the Supervisory Board, to grant one or more call options which are not limited in time and can be exercised in whole or in part, up to the authorized share capital of preference shares as per the Articles of Association at the time of exercise and at multiple times and occasions (including after the issuance and subsequent cancellation of preference

DRAFT

shares) and which can also be made conditional upon the preceding cancellation of preference shares that have been issued following the exercise of an option or otherwise.

If adopted, the proposed authorization will replace the authorization granted to the Management Board on 29 March 2019.

If and to the extent required, the proposed delegated authority to issue shares and grant rights to acquire shares also qualifies as an approving resolution within the meaning of Section 2:96(2) of the Dutch Civil Code.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 13 – Delegation to the Management Board of the authority to restrict or exclude pre-emptive rights upon the issue of shares and granting of rights to acquire shares

It is proposed to authorize the Management Board, subject to the approval of the Supervisory Board, to restrict or exclude pre-emptive rights upon the issue of shares and granting of rights to acquire shares in the capital of Kiadis up to Kiadis' authorized share capital included in its Articles of Association from time to time, and that such authorization shall be granted for a period of five years following the date of the Meeting and consequently until (and including) 25 June 2025.

For the avoidance of doubt, it is noted that if the proposal to amend the Articles of Association as per agenda item 15 is adopted and implemented, the proposed delegated authority to restrict or exclude pre-emptive rights will effectively regard and encompass such rights in relation to the issue or granting of rights to subscribe for ordinary shares only, as the proposed amendment to the Articles of Association does not attach pre-emptive rights to preference shares.

If adopted, the proposed authorization will replace the authorization granted to the Management Board on 29 March 2019.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Agenda item 14 – Authorization of the Management Board to have Kiadis Pharma repurchase shares

It is proposed to authorize the Management Board, subject to the approval of the Supervisory Board, to acquire Kiadis shares for a period of 18 months from the date of the Meeting (i.e. up to and including 25 December 2021) by way of repurchase, via the stock exchange or otherwise, up to a maximum of 10% of the issued capital and for a consideration of at least €0.01 per share and which may not exceed the average closing price on Euronext Amsterdam and Euronext Brussels during five consecutive trading days preceding the date of repurchase increased by 10%.

The proposed authorization will replace the authorization granted to the Management Board on 24 June 2019.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

DRAFT

The Chairman moves to the next item on the agenda.

Agenda item 15 – Proposal to amend the Articles of Association

In the general meeting of shareholders held on 29 March 2019, the shareholders approved a conditional amendment of the Articles of Association, introducing preference shares in Kiadis' authorized share capital. The Management Board and the Supervisory Board have decided to now implement this amendment of the Articles of Association as previously approved by the general meeting of shareholders. In addition, the Management Board and the Supervisory Board propose to make certain amendments to the Articles of Association. The proposed amendment is aimed at increasing Kiadis' authorized share capital available for ordinary shares and to allow for issuances of ordinary shares up to an increased maximum from previously 120 million shares to a new maximum for ordinary shares of 250 million shares. The proposed amendment also makes changes to the Articles of Association in view of the revised EU Shareholders' Rights Directive having come into force.

The full text of the proposal for the amendment of the Articles of Association with separate explanatory notes by way of a triptych (*drieluik*) was included in the explanatory notes to the agenda for the Meeting.

The proposal to amend the Articles of Association also includes the authorization of every member of the Management Board and every (deputy) civil-law notary, paralegal and notarial assistant at Bird & Bird (Netherlands) LLP to have the deed of amendment of the Articles of Association executed.

No questions were asked about this specific agenda item prior to the Meeting. The voting result for this agenda item are announced at the end of the Meeting (after agenda item 15).

The Chairman moves to the next item on the agenda.

Reply to questions

The Chairman and the CEO address the questions that were submitted before the Meeting, it being noted that no follow-up questions have come in during the Meeting.

A written record of the questions and answers is attached to these Minutes as Annex 1 and is made available by way of download on Kiadis' website (www.kiadis.com) after the Meeting.

Voting results

The voting results are announced and presented to the Meeting. The voting results are attached to these Minutes as Annex 2 and are made available by way of download on Kiadis' website (www.kiadis.com) after the Meeting.

Agenda item 16 – Any other business

The Chairman observes that all questions have been addressed and that there is no further business put forward to discuss.

Agenda item 17 – Closing

The Chairman closes the Meeting at 11.06 CEST.

DRAFT

Mr. Mark Wegter
Chairman of the Meeting and Chairman of the Supervisory Board
Date:

Mr. René Rieter
Secretary of the Meeting, civil law notary (*notaris*)
Date:

DRAFT

Annex 1 – Questions and Answers

Questions and answers regarding the annual general meeting of shareholders ("Meeting") of Kiadis Pharma N.V. ("Kiadis Pharma") held on Thursday 25 June 2020 at 10:00 CEST.

SHAREHOLDER QUESTION #1: Why were the shareholders' preemptive rights not provided to, and protected for, all shareholders for the April 2020 equity raise?

SHAREHOLDER QUESTION #2: Why was an affiliate of LSP (who was indisputably a then-current shareholder as of April 2020) given the opportunity to participate in the April 2020 equity raise, but no other then-current shareholder(s) or other current shareholder affiliates were given the opportunity to participate?

KIADIS REPLIES #1 and #2: The questions #1 and #2 will be answered jointly as these both touch upon the theme of equity raises and the position of existing shareholders therein. Since our IPO and Euronext listing, all of our equity raises have been done by means of private placements with institutional investors and we have never done a fundraising open to all our shareholders based on pre-emptive rights. Raising equity by means of a private placement with institutional investors is very typical for Dutch listed companies whereas a share offering based on pre-emptive rights is atypical.

Furthermore, with reference to Dutch corporate law, corporate practice and agenda item #6 of our EGM of 29 March 2019: the Management Board may restrict or exclude pre-emptive rights upon share issue up to the authorized share capital.

SHAREHOLDER QUESTION #3: Were any members of the Management Board or Supervisory Board involved or associated in any way, by direct or indirect ownership, management or other relationship, with any of the entities that participated in the April 2020 equity raise other than Messrs. Mark Wegter and Martijn Kleijwegt? If yes, who were they?

KIADIS REPLY #3: No.

SHAREHOLDER QUESTION #4: Given that the CytoSen group of shareholders have access to capital and each have sophisticated investment knowledge, and recognizing that all members of that group are sophisticated investors, can and will each be offered the same opportunities to participate in all future equity raises as was LSP in the April 2020 equity raise? If no, why not?

KIADIS REPLY #4: We cannot comment on, or commit to, anything related to future funding. Decisions on subsequent funding will be made in the future based on circumstances at that time. Reference is also made to our reply on question #1 above regarding the customary funding routes in The Netherlands.

SHAREHOLDER QUESTION #5: When should the Management Board and/or Supervisory Board or any of their members have known that the CHMP was going to issue a negative opinion and recommend against conditional marketing authorization for ATIR01? When did the Management Board or Supervisory Board or any of their members know?

SHAREHOLDER QUESTION #6: When should Kiadis have known that that the standard of care relative to ATIR101 had changed to include the Baltimore protocol? When did Kiadis know?

SHAREHOLDER QUESTION #7: When should Kiadis have known that revenue expectations in the initial years of European launch of ATIR101 would be minimal? When did Kiadis know?

KIADIS REPLIES #5, #6 and #7: The questions #5, #6 and #7 will be answered jointly as these all seem to touch upon the theme of disclosure.

Kiadis Pharma attaches great value to the timely and proper disclosure of material and/or price sensitive information in compliance with all relevant laws and regulations (amongst others, the EU Market Abuse Regulation). In line with such applicable legislation, Kiadis Pharma has at all times fully informed its investors / shareholders with regard to material information without delay. This is evident from, among other things, press releases and investor presentations that are available on the Kiadis Pharma website and the website of the Dutch Authority for the Financial Markets (*Autoriteit Financiële Markten* – the "AFM").

SHAREHOLDER QUESTION #8: Is the Management Board and/or Supervisory Board aware of any pending or threatened litigation against Kiadis, its subsidiaries and/or its board members? If yes, what litigation is pending or has been threatened?

KIADIS REPLY #8: Reference is made to paragraph 3.7 (page 57) of the Registration Document that Kiadis Pharma published on 5 June 2020 and is accessible via the Kiadis Pharma website and the website of the AFM.

SHAREHOLDER QUESTION #9: What percentage of the issued shares of capital stock in Kiadis is owned directly or indirectly by each member (identified by name) of the Management Board and/or by each member (identified by name) of the Supervisory Board, including in such response the identity and percentage of shares owned by each entity owned, managed or controlled, directly or indirectly, by each member of the Management Board and/or the Supervisory Board?

KIADIS REPLY #9: Regarding individual securities holdings in Kiadis Pharma by members of our Management Board and Supervisory Board, reference is made to the Registration Document that Kiadis Pharma published on 5 June 2020 and is accessible via the Kiadis Pharma website and the website of the AFM and to the publicly available registers of the AFM that are accessible via the AFM website.

Annex 2 – Voting Results

Voting results of the annual general meeting of shareholders ("Meeting") of Kiadis Pharma N.V. ("Kiadis Pharma") held on Thursday 25 June 2020 at 10:00 CEST.

Number of shares represented: 15,080,891
 % of issued share capital: 37.66%⁽¹⁾

Agenda item - Resolution	# Votes cast	% Votes cast⁽¹⁾	For	Against	Abstain	Result
Agenda item 3 - Advisory vote on the Remuneration Report for 2019	14,127,982	35.28%	13,735,203	392,779		Adopted
Agenda item 4 - Proposal to adopt the Financial Statements for 2019	14,127,982	35.28%	13,897,450	230,532	952,909	Adopted
Agenda item 5 - Proposal to release from liability the members of the Management Board	15,080,891	37.66%	13,897,450	1,183,441	0	Adopted
Agenda item 6 - Proposal to release from liability the members of the Supervisory Board	15,080,891	37.66%	13,897,450	1,183,441	0	Adopted
Agenda item 7 - Proposal to adopt revised Remuneration Policy for the Management Board and the Supervisory Board	14,127,982	35.28%	13,735,203	392,779	952,909	Adopted
Agenda item 8 – Proposal to adopt remuneration of members of the Supervisory Board, including the granting of options	15,080,891	37.66%	13,735,203	1,345,688	0	Adopted
Agenda item 9 - Proposal to reappoint Dr. Robert Soiffer as a member of the Supervisory Board	15,080,891	37.66%	13,736,019	1,344,872	0	Adopted
Agenda item 10 - Proposal to reappoint Mr. Berndt Modig as a member of the Supervisory Board	15,080,891	37.66%	13,736,019	1,344,872	0	Adopted
Agenda item 11 - Proposal to appoint KPMG Accountants N.V. as Kiadis' external auditor for the financial year 2020	15,080,891	37.66%	14,850,359	230,532	0	Adopted
Agenda item 12 - Proposal to delegate to the Management Board the authority to issue shares and to grant rights to acquire shares	15,080,891	37.66%	13,735,203	1,345,688	0	Adopted
Agenda item 13 - Proposal to delegate to the Management Board the authority to restrict or exclude pre-emptive rights upon	15,080,891	37.66%	13,735,203	1,345,688	0	Adopted

DRAFT

the issue of shares and granting of rights to acquire shares						
Agenda item 14 - Proposal to authorize the Management Board to have Kiadis Pharma repurchase shares	15,080,891	37.66%	13,987,450	1,183,441	0	Adopted
Agenda item 15 – Proposal to amend the Kiadis Pharma articles of association	15,080,891	37.66%	13,735,203	1,345,688	0	Adopted

⁽¹⁾ *Percentage of the issued share capital as at the record time of the Meeting, being 40,041,489 shares, each carrying one (1) voting right.*

DRAFT